The earnings call reflects strong growth in revenue and successful pipeline developments, with significant achievements in the oncology segment and positive Phase III trial results. However, challenges persist in China and from Medicare Part D reform, with concerns about the loss of exclusivity for some products.

Company Guidance

During the AstraZeneca 9 months and Q3 2025 call, the company reiterated its strong performance and guidance metrics. Total revenue increased by 11%, with core EPS rising by 15%. The oncology franchise saw a 16% growth, while the Biopharmaceuticals and Rare Disease franchises grew by 8% and 6%, respectively. The company achieved 31 regulatory approvals and announced positive outcomes from 16 Phase III trials. Cash flow from operating activities increased by 37% to $12.2 billion. AstraZeneca maintained its full-year guidance, expecting total revenue to increase by high single digits and core EPS by low double digits, both at constant exchange rates. The company also highlighted its $80 billion revenue ambition for 2030 and a mid-30s core operating margin target for 2026.

Strong Revenue Growth

Total revenue grew by 11% in the first 9 months of 2025, driven by a strong demand for innovative medicines, with core EPS increasing by 15%.

Oncology Segment Success

Oncology revenue grew 16% to $18.6 billion, with strong growth in the U.S. (19%) and emerging markets (20%).

Impressive Pipeline Developments

Achieved 31 regulatory approvals and positive results from 16 Phase III trials, with six data sets presented in plenary sessions at major conferences.

Successful Product Launches and Growth

Products like Tagrisso, Calquence, and Enhertu showed significant growth, with Enhertu revenues growing by 39% in the third quarter.

Positive Phase III Trial Results

Positive high-level results for Phase III Bax24 trial and TROPION-Breast02, showcasing significant improvements in treatment outcomes.

New U.S. Government Agreement

Landmark agreement with the U.S. government providing clarity around pricing and a 3-year exemption from tariffs.

AstraZeneca (AZN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AZN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 05, 2026	2025 (Q4)	1.07 / -	1.045	―	―	―
Nov 06, 2025	2025 (Q3)	1.19 / 1.19	1.04	14.42% (+0.15)
Jul 29, 2025	2025 (Q2)	1.08 / 1.08	0.99	9.60% (+0.09)
Apr 29, 2025	2025 (Q1)	1.13 / 1.25	1.03	20.87% (+0.22)
Feb 06, 2025	2024 (Q4)	1.03 / 1.04	0.725	44.14% (+0.32)
Nov 12, 2024	2024 (Q3)	1.02 / 1.04	0.865	20.23% (+0.18)
Jul 25, 2024	2024 (Q2)	0.98 / 0.99	1.075	-7.91% (-0.08)
Apr 25, 2024	2024 (Q1)	0.96 / 1.03	0.96	7.29% (+0.07)
Feb 08, 2024	2023 (Q4)	0.73 / 0.72	0.69	5.07% (+0.04)
Nov 09, 2023	2023 (Q3)	0.84 / 0.86	0.835	3.59% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AZN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	$81.15	$83.77	+3.23%
Jul 29, 2025	$71.34	$73.48	+3.00%
Apr 29, 2025	$69.46	$71.22	+2.53%
Feb 06, 2025	$69.48	$70.88	+2.01%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.